Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem
Chỉ hiển thị Multimedia

Real-world study supports new therapeutics for BRAF-mutant metastatic CRC
07 Sep 2026
bởiAudrey Abella
A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).
07 Sep 2026







